huHSC-(Kit-V831M M-NSG)

Fig 1 . Body weight growth curves of M-NSG and Kit-V831M (M-NSG) mice post human HSC inoculation. Human CD34+ HSCs (1E5) were intravenously injected into homozygous Kit-V831M (M-NSG) (n=8, female, 5-7 weeks) and M-NSG mice (n=6, female, 4 weeks). All mice were subjected a 1.0 Gy irradiation prior to cell inoculation. 

Fig 2. Humanized immune reconstitution levels in M-NSG and Kit-V831M (M-NSG) mice engrafted with human HSC. Human CD34+ HSCs (1E5) were intravenously injected into homozygous Kit-V831M (M-NSG) (n=8, female, 5-7 weeks) and M-NSG mice (n=6, female, 4 weeks). All mice were subjected a 1.0 Gy irradiation prior to cell inoculation. 

Fig 3. Survival rates of female M-NSG and huHSC-Kit-V831M (M-NSG) mice post human HSC inoculation. Human CD34+ HSCs (1E5) were intravenously injected into homozygous Kit-V831M (M-NSG) (n=8, female, 5-7 weeks) and M-NSG mice (n=6, female, 4 weeks). All mice were subjected a 1.0 Gy irradiation prior to cell inoculation. 

Fig 4. Flow cytometry analysis of peripheral blood lymphocyte subpopulations. 1E5 human CD34⁺ HSCs from the same donor were i.v. transplanted into non-irradiated Kit-V831M (M-NSG) and irradiated (1.0 Gy) M-NSG mice. From week 12 onward, mice in group G2 were treated with clodronate liposomes (Clo-lip) via i.v. injection every 5 days. Weekly monitoring was performed to evaluate mouse macrophage depletion and human red blood cell (RBC) reconstitution. Clo-lip effectively depleted circulating mouse macrophages, enabling RBCs generated in the bone marrow to enter circulation, thereby facilitating reconstitution of human RBCs in the peripheral blood. (Female, 4-5 weeks old, n=8-10). 

Fig 5. Body weight growth curve. 1E5 human CD34⁺ HSCs from the same donor were i.v. transplanted into non-irradiated Kit-V831M (M-NSG) and irradiated (1.0 Gy) M-NSG mice. From week 12 onward, mice in group G2 were treated with clodronate liposomes (Clo-lip) via i.v. injection every 5 days. Following Clo-lip treatment, into Kit-V831M (M-NSG) mice exhibited body weight loss, which may be attributed to the drug-related toxicity of Clo-lip. (Female, 4-5 weeks old, n=8-10). 

Fig 6. Percentage of survival. 1E5 human CD34⁺ HSCs from the same donor were i.v. transplanted into non-irradiated Kit-V831M (M-NSG) and irradiated (1.0 Gy) M-NSG mice. From week 12 onward, mice in group G2 were treated with clodronate liposomes (Clo-lip) via i.v. injection every 5 days. Following Clo-lip treatment, into Kit-V831M (M-NSG) mice exhibited increased mortality, which may be attributed to the drug-related toxicity of Clo-lip. (Female, 4-5 weeks old, n=8-10).  

品系背景验证数据见 Kit-V831M(M-NSG) NM-KI-242813，点击下方链接了解详情：

Kit-V831M(M-NSG)-南模生物